Comprehensive clinical characterization of patients with BRCA1: c.5017_5019del germline variant
10.4174/astr.2022.103.6.323
- Author:
Yoon Ju BANG
1
;
Won Kyung KWON
;
Jong-Won KIM
;
Jeong Eon LEE
;
Boo Yeon JUNG
;
Mina KIM
;
Jisun KIM
;
Jeongshin AN
;
Seung Pil JUNG
;
Hong-Kyu KIM
;
Zisun KIM
;
Hyun Jo YOUN
;
Jai Min RYU
;
Sung-Won KIM
;
Author Information
1. Department of Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Annals of Surgical Treatment and Research
2022;103(6):323-330
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:We provide evidence for the reclassification of the BRCA1:c.5017_5019del variant by presenting the clinicopathological characteristics, clinical outcomes, and family history of breast or ovarian cancer in 17 patients with this variant.
Methods:This study included breast or ovarian cancer patients tested for BRCA1/2 genes between January 2008 and June 2020 at 10 medical centers in Korea. We retrospectively reviewed 17 probands from 15 families who had the BRCA1:c.5017_5019del variant according to the electronic medical records.
Results:We present 10 breast cancer patients and 7 ovarian cancer patients from 15 families identified as having BRCA1:c.5017_5019del and a total of 19 cases of breast cancer and 14 cases of ovarian cancer in these families. The ratio of breast-to-ovarian cancer was 1.3:1. Breast cancer patients with this variant showed a rich family history of breast or ovarian cancer, 8 patients (80.0%). The mean age at diagnosis was 45.4 years and 6 patients (60.0%) were categorized into hormone-receptor–negative breast cancer. Also, the ovarian cancer patients with this variant showed strong family histories of breast and/or ovarian cancer in 4 patients (57.1%).
Conclusion:We presented clinical evidence for the reclassification of BRCA1:c.5017_5019del as a likely pathogenic variant (LPV). Reclassification as LPV could result in the prophylactic treatment and medical surveillance of probands, family testing recommendations, and appropriate genetic counseling of their families.
